logo-loader
viewSalarius Pharmaceuticals

Salarius Pharmaceuticals CEO talks through recent achievements for its lead cancer drug candidate

Salarius Pharmaceuticals (NASDAQ:SLRX) CEO David Arthur sat down with Proactive at the Biotech Showcase 2020 in San Francisco. The Texas-based oncology company's lead candidate, Seclidemstat, is currently in clinical development to treat Ewing sarcoma. Seclidemstat has been granted Orphan Drug designation and Pediatric Rare Disease Designation by the FDA.

Quick facts: Salarius Pharmaceuticals

Price: 2.86 USD

NASDAQ:SLRX
Market: NASDAQ
Market Cap: $11.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Ceres Power eyes expansion following new Bosch deal

This month German engineering firm Bosch increased its stake in Ceres Power Holdings (LON:CWR) to around 18% from 4% following a share subscription, netting Ceres £38mln. It was Bosch that approached Ceres too, pinpointing Ceres steel fuel cell technology as potentially the best in the...

3 hours, 12 minutes ago

2 min read